

DIASORIN LAUNCHES THE TEST FOR CALPROTECTIN FOR STOOL TESTING

THE FASTEST AND MOST FLEXIBLE TEST ON THE MARKET TO IDENTIFY INFLAMMATORY BOWEL DISEASES, SPECIFICALLY CROHN'S DISEASE AND ULCERATIVE COLITIS, BEFORE USING INVASIVE AND COSTLY COLONOSCOPY METHOD

January 14, 2015 - Saluggia (VC) - **DiaSorin** (FTSE Mid Cap: DIA) **launched the test for the quantitative determination of Calprotectin in stool samples**, available outside the US only.

After having completed the panel for Gastro-Intestinal infections, DiaSorin launched the first completely automated test for Gastro-Intestinal tract inflammatory diseases, expanding its CLIA offer on LIAISON platforms in a growing market.

"Until today, the first approach to a patient suffering with strong symptoms of inflammatory bowel diseases (IBD) was to use a colonoscopy exam, which is a costly and invasive methodology that requires long delays to get results, sometimes up to three weeks", as Francesco Colotta, Chief Medical Officer in DiaSorin, commented.

"Our clients' request to us was to solve these limitations through a more flexible, non-invasive and fast solution that would allow identifying those patients that really needed a further diagnostic investigation".

The LIAISON **Calprotectin test is DiaSorin's answer** to the market to aid in discriminating irritable bowel syndrome (caused by disorder of intestinal function) from inflammatory chronic bowel diseases (IBD), and allow the diagnosis of the **Crohn's disease** and **ulcerative colitis**.

The available clinical data on the incidence and spread of inflammatory bowel diseases show a steady increase in the world, being able to qualify them today as **global diseases**.

Europe, in particular, represents a market of about 9 million Euros, growing 20% year on year.

Carlo Rosa, Chief Executive Officer of DiaSorin Group, commented: *"The stool testing diagnostic market continues to be for us one of the most important growth-drivers for the future.*

The success gained with tests for gastrointestinal infections drives us to expand our offering also to the inflammatory and autoimmune gastrointestinal diseases markets.

With the launch of Calprotectin, DiaSorin proves again to be strongly committed to becoming a significant player in this market and to support its customers with innovative, quick and quality solutions to meet their daily needs".

REFERENCE TABLE FOR DIASORIN PRODUCTS

Assay name	Calprotectin		
Diagnosis	Quantitative determination of Calprotectin in stool samples		
Business segment	Immunodiagnosics	✓	Molecular Diagnostics
Potential market	Europe: € 9 mln		
Technology	CLIA	✓	Extraction
	ELISA		Amplification/Detection
	RIA		
Clinical Area	Infectious Disease		Infectious Disease
	Hepatitis and Retroviruses		
	Oncology & Endocrinology		Onco-hematology
	Bone & Mineral		
	Cardiac Markers		
GI Stool Testing	✓		

About DiaSorin

Headquartered in Italy and listed in the FTSE Mid Cap Index, DiaSorin is a global leader in the In Vitro Diagnostics (IVD) field. For over 40 years the Company has been developing, producing and marketing reagent kits for IVD worldwide. Through constant investments in research and development, and using its own distinctive expertise in the field of immunodiagnosics to deliver a high level of innovation, DiaSorin offers today the broadest range of specialty tests available in the immunodiagnosics market and new tests in the molecular diagnostics markets which identify DiaSorin Group as the IVD “diagnostics specialist”.

For additional information, please contact:

Riccardo Fava
 Investor Relations & Corporate Communication Director
 Tel: +39.0161.487988
riccardo.fava@diasorin.it

Margherita Sacerdoti
 Investor Relations Specialist
 Tel: +39.0161.487456
margherita.sacerdoti@diasorin.it